NCT03742102: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.

NCT03742102
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment for metastatic (Stage IV) TNBC or untreated CNS metastases
https://ClinicalTrials.gov/show/NCT03742102

Comments are closed.

Up ↑